Wolffia Globosa (Mankai)- aquatic plant

Dataset

Description

The investigators aim to test the protein bioavailability of a new species that developed a strain of duckweed [Wolffia globose, Mankai]. This aquatic plant might serve as a protein source and contains all the nine essential and six conditional amino acids. The investigators will randomize 36 participants to consume equivalent protein (30gr) content of 3 whole foods items: 1. White cheese (animal protein source, as a reference); 2. Green peas, intact, cooked (plant protein source); 3. Wolffia globosa (Mankai), entire, cooked (plant protein source). The foods will be consumed in the morning, following 12h fasting. The foods will be provided with 250ml mineral water, and the blood follow-up frame will be for 3 hours—primary outcome: Blood amino acid profile.
--------------------------------------------------------
Type 2 diabetes is a significant public health concern in Western societies. Type 2 diabetes is associated with high morbidity and shorter life expectancy. In patients with type 2 diabetes maintaining glycemic control is associated with lower rates of complications and mortality associated with the disease. Thus, there is a great need to recognize nutritional elements that improve glycemic control and insulin sensitivity in patients with type 2 diabetes. Mankai, a strain of Wolffia globosa recently developed under controlled conditions, is characterized by high protein content and good bioavailability of proteins, rich in soluble fiber, vitamins (including vitamin B12), minerals (including iron and zinc), omega-three fatty acids, and polyphenols. The 18-month long DIRECT PLUS trial was a weight-loss intervention conducted among 294 participants with abdominal obesity or dyslipidemia. Ninety-eight of the study participants were assigned to a green Mediterranean diet intervention and instructed to consume four frozen cubes of Mankai daily. The main conclusions from the DIRECT PLUS refer to the beneficial effect of the green-Mediterranean diet on cardiometabolic risk, gut bacteria, and liver fat, with no evidence of disadvantages or adverse effects of long-term Mankai consumption. In 2019, the investigators reported that among non-diabetics and those with fasting glucose levels within the normal range, consuming a Mankai smoothie in the evening led to lower glucose levels after the meal and lower fasting overnight compared to a yogurt smoothie. The investigators now plan to explore the effect of Mankai daily supplementation on post-meal glycemic response in participants with type 2 diabetes. The investigators hypothesize that adding Mankai consumption after a meal may mitigate glucose excursions compared with control.
Date made available9 Jan 2017
Publisherclinicaltrials.gov
Date of data production1 Dec 2016 - 18 Nov 2021

Cite this